RNN Share Price

Open 2.37 Change Price %
High 2.37 1 Day -0.08 -3.39
Low 2.25 1 Week 0.01 0.44
Close 2.28 1 Month -0.71 -23.75
Volume 119038 1 Year 2.02 776.92
52 Week High 4.74
52 Week Low 0.13
RNN Important Levels
Resistance 2 2.39
Resistance 1 2.35
Pivot 2.30
Support 1 2.21
Support 2 2.17
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
BTI 69.85 1.67%
BTI 69.85 1.67%
RBY 0.03 -70.00%
NGD 3.09 -2.52%
NGD 3.09 -2.52%
PBTH 8.23 0.37%
GGR 0.02 100.00%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
IG 7.68 22.49%
More..
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
CUR 1.75 -29.15%
CUR 1.75 -29.15%
CUR 1.75 -29.15%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
More..

Rexahn Pharmaceuticals, Inc. (AMEX: RNN)

RNN Technical Analysis 2
As on 27th Jul 2017 RNN Share Price closed @ 2.28 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.98 & Strong Sell for SHORT-TERM with Stoploss of 3.16 we also expect STOCK to react on Following IMPORTANT LEVELS.
RNN Target for July
1st Target up-side 3.72
2nd Target up-side 4.32
3rd Target up-side 4.92
1st Target down-side 2
2nd Target down-side 1.4
3rd Target down-side 0.8
RNN Other Details
Segment EQ
Market Capital 39568448.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.rexahn.com
RNN Address
RNN
15245 Shady Grove Road
Suite 455
Rockville, MD 20850
United States
Phone: 240-268-5300
Fax: 240-268-5310
RNN Latest News
Rexahn Pharmaceuticals Inc 2016 Q4 Institutional Investor Sentiment Worse Than ...   WeeklyHub   - 27th Jul 17
Rexahn Pharmaceuticals Receives Notice of Allowance for a New US Patent ...   GlobeNewswire (press release)   - 10th Jul 17
Breakfast Technical Briefing on Biotech Stocks -- Rexahn Pharma, Novavax, and ...   PR Newswire (press release)   - 14th Jun 17
Rexahn Announces $10 Million Registered Direct Offering   GlobeNewswire (press release)   - 07th Jun 17
Could Rexahn Pharmaceuticals Have Something?   Seeking Alpha   - 17th Apr 17
Rexahn Announces 1-for-10 Reverse Stock Split   GlobeNewswire (press release)   - 13th Apr 17
Rexahn Pharmaceuticals (RNN) Jumps: Stock Moves Up 5.4% March 16, 2017   Zacks.com   - 16th Mar 17
Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides ...   GlobeNewswire (press release)   - 27th Feb 17
Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical ...   GlobeNewswire (press release)   - 20th Jan 17
Rexahn Pharmaceuticals to Present Trial Data (RNN)   Investopedia   - 06th Oct 16
Interactive Technical Analysis Chart Rexahn Pharmaceuticals, Inc. ( RNN AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Rexahn Pharmaceuticals, Inc.
RNN Business Profile
Rexahn Pharmaceuticals, Inc., a development stage biopharmaceutical company, is engaged in the discovery, development, and commercialization of treatments for cancer and other medical needs. Its clinical stage oncology candidates comprise Archexin, an inhibitor of the protein kinase Akt, which has completed a Phase IIa clinical trials for the treatment of pancreatic cancer; RX-3117, a small molecule nucleoside compound with an anti-metabolite mechanism of action that is in Phase Ib clinical trials for the treatment of solid tumors; and RX-5902, a small molecule that inhibits the phosphorylation of p68 RNA helicase, which is in Phase I clinical trials for the treatment of solid tumors. The company’s pre-clinical product pipeline consists of RX-0047-Nano, a nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101, an anticancer nano-polymer drug. It has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries, Ltd.; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; Ohio State University; Revaax Pharmaceuticals LLC; and Rexgene Biotech Co., Ltd. The company is based in Rockville, Maryland.